Key result
A slow-release twice-daily formulation of nifedipine may induce myocardial ischemia through a heart-rate increase and a decrease in coronary blood flow due to lower diastolic BP.
Why the study?
Does a slow-release twice-daily formulation of nifedipine affect ambulatory blood pressure and ischemic changes on ECG in patients with severe coronary artery disease?
Does a slow-release twice-daily formulation of nifedipine affect ambulatory blood pressure and ischemic changes on ECG in patients with severe coronary artery disease?
Slow-release twice-daily nifedipine may paradoxically induce myocardial ischemia in patients with severe CAD due to reflex tachycardia and diastolic hypotension.
Warrants caution with twice-daily nifedipine in severe CAD; hypothesis-generating case report requiring prospective confirmation.
Calcium antagonists have long been used as first-line drugs for hypertension and angina. However, deleterious effects have also been reported in patients treated with calcium antagonists. Thus, we evaluated the effect of a slow-release twice-daily formulation of nifedipine in 10 patients with severe coronary artery disease. Twenty-four-hour ambulatory electrocardiography (AECG) and blood pressure monitoring (ABPM) were performed simultaneously to detect any association between ischemic episodes on the ECG and changes in blood pressure (BP) and heart rate with and without nifedipine. Increased oxygen demand due to an increased systolic BP and heart rate was associated with ischemic episodes without nifedipine, while those with nifedipine were accompanied by a fall in diastolic BP and a rapid increase in heart rate. This slow-release twice-daily formulation of nifedipine may induce myocardial ischemia through a heart-rate increase and a decrease in coronary blood flow due to lower diastolic BP in patients with severe coronary artery disease. A once-daily formulation of nifedipine might be of great value for such patients.
No takes yet. Share an insight, caveat, or question.
Matsumoto et al. (2000) studied severe coronary artery disease (n=10). slow-release twice-daily formulation of nifedipine vs. without nifedipine was evaluated on association between ischemic episodes on the ECG and changes in blood pressure and heart rate. A slow-release twice-daily formulation of nifedipine may induce myocardial ischemia through a heart-rate increase and a decrease in coronary blood flow due to lower diastolic BP.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: